Genestra Super Lipoic Acid 60 Capsules
Genestra Super Lipoic Acid- 60 capsules
• Alpha Lipoic Acid formula • An antioxidant for the maintenance of good health (1), and reduces symptoms of neuropathy in Type II diabetes (2) • Ideal for vegans • Convenient capsule format increase patient compliance
Super Lipoic Acid provides a source of this ingredient as an antioxidant for the maintenance of good health (3). The capsules are 100% pure vegetable-sourced.
References: 1 NHPD AbLS on Alpha lipoic acid, DL-. September 2009. 2 Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. 3 NHPD AbLS on Alpha lipoic acid, DL-. September 2009.
Additional product info: Alpha Lipoic Acid, not to exceed 600 mg per day, provides antioxidants for the maintenance of good health, and at 600 mg per day, helps promote healthy glucose metabolism (4).
In vitro studies have shown that alpha-lipoic acid (LA) is an antioxidant. The aim of a study was to assess the effect of oral supplementation with LA alone and in combination with alpha-tocopherol (AT) on measures of oxidative stress. A total of 31 healthy adults were supplemented for 2 months either with LA (600 mg/day), or with AT (400 IU/day) alone, and then with the combination of both for 2 additional months. LA significantly increased the lag time of low-density lipoprotein (LDL) lipid peroxide formation for both copper-catalyzed and 2,2’-azobis (2-amidinopropane) hydrochloride (AAPH)-induced LDL oxidation, decreased urinary F2-isoprostanes levels, and plasma carbonyl levels after AAPH oxidation. In conclusion, LA supplementation functions as an antioxidant, because it decreases plasma- and LDL-oxidation and urinary isoprostanes (5).
The aim of a trial was to evaluate the effects of alpha-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients received once-daily oral doses of 600 mg, 1,200 mg, and 1,800 mg of ALA or placebo for 5 weeks after a 1-week placebo run-in period. Mean Total Symptom Score (TSS) did not differ significantly at baseline among the treatment groups and decreased in treatment groups compared to the placebo group. Significant improvements favoring all three ALA groups were also noted for stabbing and burning pain, the Neuropathy Symptoms and Change (NSC) score, and the patients' global assessment of efficacy. The Neuropathy Impairment Score (NIS) was numerically reduced. Oral treatment with ALA for 5 weeks improved neuropathic symptoms and deficits in patients with DSP (6).
The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction. The ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, on endothelial function and inflammation was evaluated in patients with the metabolic syndrome. 58 subjects with the metabolic syndrome were randomized in a double-blinded manner to irbesartan 150 mg/d, lipoic acid 300 mg/d, both irbesartan and lipoic acid, or matching placebo for 4 weeks. After 4 weeks of therapy, endothelium-dependent flow-mediated vasodilation of the brachial artery was increased in the irbesartan, lipoic acid, and irbesartan plus lipoic acid groups, compared with the placebo group. Treatment with irbesartan and/or lipoic acid was associated with statistically significant reductions in plasma levels of interleukin-6 and plasminogen activator-1. Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis (7).
References: 4 NHPD AbLS on Alpha lipoic acid, DL-. September 2009. 5 Marangon K, Devaraj S, Tirosh O, Packer L, Jialal I. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med. 1999 Nov;27(9-10):1114-21. 6 Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. 7 Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343-8.